Can I Stay on a Low Dose of Wegovy Long Term?

What the trial data tells us about dose and weight loss

The STEP 1 trial, published in the New England Journal of Medicine, enrolled over 1,900 adults with obesity and no diabetes over 68 weeks. Participants titrating to the 2.4mg maintenance dose achieved an average body-weight reduction of around 15%. That headline figure shaped the licensed schedule: start at 0.25mg, increase roughly every four weeks, with 2.4mg as the target. The trial wasn't designed to test long-term low-dose maintenance, which is exactly why clinicians can't simply assume a lower dose will do the same job.

What the evidence does show is that weight-loss response is highly individual. Some people experience strong early results and significant side effects at higher doses; others plateau despite reaching 2.4mg. Neither pattern is a personal failing. Biology, starting weight, diet, activity and other medicines all shape the outcome. That variability is part of why prescribers review each case individually rather than applying a single path.

For people wondering whether they can stay on Wegovy at 0.5mg, the honest answer is: it depends on what that dose is doing for you. A dose that is producing meaningful, sustained weight loss with manageable side effects is a dose worth discussing with your prescriber. One that has stalled progress for months probably isn't serving you well at that level.

How Wegovy's titration schedule actually works, and where low-dose staying fits

The full Wegovy dose ladder runs from 0.25mg through 0.5mg, 1mg and 1.7mg before reaching the 2.4mg maintenance dose. The earlier rungs are primarily tolerability steps: they allow your body to adjust to semaglutide before the dose that the trial evidence associates with meaningful weight management. The 2.4mg maintenance dose is where the STEP 1 results were largely observed.

Staying at 0.5mg, 1mg or 1.7mg for an extended period sits outside the standard licensed pathway, that doesn't make it automatically wrong, but it does mean your prescriber needs a clear clinical reason. Common legitimate reasons include persistent gastrointestinal side effects that don't settle after an increase, or a medical change that calls for caution. Holding at a lower dose of Wegovy can be appropriate; remaining there indefinitely without clinical review is not something to arrange without a prescriber's input.

It's also worth noting that the MHRA-approved 7.2mg higher-dose pen, cleared in April 2026, moves in the opposite direction for patients whose prescribers judge they need more. The existence of that option underlines the same point: the dose that is right for you is the one your prescriber sets, not the one you land on by default.

NICE guidance and the 5% weight-loss threshold

NICE's appraisal of semaglutide for weight management (TA875) includes a clear stopping rule: if a patient has not achieved at least 5% weight loss after six months on the maintenance dose, continuing treatment should be reviewed. This applies to the maintenance dose, not to the titration phase.

The implication for lower-dose decisions is practical. If you stay at, say, 1mg long term and that dose isn't producing meaningful progress, the NICE stopping-rule logic still applies, the medicine isn't doing enough to justify ongoing use at that dose. Conversely, if a lower dose is producing steady, sustained loss without intolerable side effects, your prescriber may judge there is a clinical case for holding rather than pushing higher. That's a proper clinical conversation, with a prescription review, not a decision to make quietly by skipping an increase.

For those managing costs alongside treatment, Wegovy pricing across providers is worth understanding, the lower doses don't automatically cost less through every clinic, and switching provider mid-titration adds clinical complexity.

What staying on a low dose means in practice for your prescriber

A prescriber holding you at a lower Wegovy dose is not cutting corners. They are applying clinical judgement. What they need from you is honest reporting: actual weight changes, how side effects have evolved, any other medicines or conditions that have changed. Without that, the review becomes guesswork.

At nume, a real clinician reads your information the same day, not software. Every repeat order goes through a fresh clinical check. If you're on a lower dose and thinking about whether to stay there or move up, that's exactly the kind of question to raise during your review, not to answer on your own by staying quiet at repeat stage. Our clinical team deals with dose-hold questions regularly. Payday falling mid-month, a holiday making the fridge less accessible, a fortnight of nausea after an increase, these are all things that come up, and they're all things a prescriber can account for when it's raised.

If you haven't started treatment yet and want to understand how the process works, check your eligibility with a free consultation. If you're already mid-titration and unsure, the right move is the same: speak to whoever is prescribing for you, clearly and soon.